- Paraneoplastic Neurologic Syndrome (PNS) is gaining increasing attention within the healthcare industry due to its complex autoimmune nature, often associated with underlying malignancies. As diagnostic capabilities and clinical awareness improve, the demand for early detection and targeted treatment is rising globally
- The growth of the PNS market is largely driven by increasing prevalence of cancer, heightened awareness among clinicians, rising demand for immunotherapy, and the growing availability of diagnostic biomarkers specific to paraneoplastic syndromes
- North America dominated the paraneoplastic neurologic syndrome market, accounting for the largest revenue share of 39.4% in 2024, attributed to early adoption of advanced diagnostic tools, robust cancer screening programs, strong research and development activities, and high healthcare spending
- Asia-Pacific is projected to be the fastest-growing region in the paraneoplastic neurologic syndrome market during the forecast period, driven by rising cancer incidence rates, increasing urbanization, improved healthcare infrastructure, and rising disposable incomes across countries such as China, India, and Japan
- The parenteral segment dominated the paraneoplastic neurologic syndrome market with a market share of 58.3% in 2024, owing to its rapid-effect delivery routes and suitability for administering critical therapies such as intravenous immunoglobulin (IVIg), corticosteroids, and plasmapheresis. This route is widely adopted in hospital settings and specialized neurology units for acute and severe cases requiring immediate therapeutic intervention
